Aldeyra Therapeutics’ (ALDX) “Outperform” Rating Reaffirmed at Cowen and Company
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)‘s stock had its “outperform” rating reaffirmed by Cowen and Company in a report issued on Thursday, The Fly reports. They currently have a $14.00 price objective on the biotechnology company’s stock, up from their prior price objective of $9.00. Cowen and Company’s target price would suggest a potential upside of 115.38% from the company’s current price.
A number of other research firms have also recently weighed in on ALDX. HC Wainwright set a $18.00 target price on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Thursday, June 15th. ValuEngine cut shares of Aldeyra Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. Canaccord Genuity restated a “buy” rating and set a $27.00 price target (up from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday. Zacks Investment Research cut shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 30th. Finally, Stifel Nicolaus restated a “buy” rating and set a $16.00 price target on shares of Aldeyra Therapeutics in a research note on Wednesday, May 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $15.95.
Aldeyra Therapeutics (NASDAQ ALDX) opened at 6.35 on Thursday. Aldeyra Therapeutics has a one year low of $3.80 and a one year high of $8.19. The stock’s 50 day moving average is $4.40 and its 200 day moving average is $4.66. The company’s market capitalization is $39.66 million.
Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.02. On average, analysts anticipate that Aldeyra Therapeutics will post ($1.63) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/14/aldeyra-therapeutics-aldx-outperform-rating-reaffirmed-at-cowen-and-company.html.
In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive purchased 296,007 shares of the company’s stock in a transaction that occurred on Friday, June 30th. The shares were bought at an average cost of $4.60 per share, for a total transaction of $1,361,632.20. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 28.40% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Virtu KCG Holdings LLC purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $104,000. Renaissance Technologies LLC purchased a new stake in shares of Aldeyra Therapeutics during the 1st quarter valued at approximately $132,000. Hikari Power Ltd lifted its stake in shares of Aldeyra Therapeutics by 186.4% during the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after buying an additional 70,196 shares in the last quarter. Sabby Management LLC purchased a new stake in shares of Aldeyra Therapeutics during the 1st quarter valued at approximately $898,000. Finally, Vanguard Group Inc. lifted its stake in shares of Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after buying an additional 9,407 shares in the last quarter. Institutional investors own 49.09% of the company’s stock.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.